Illumina (NASDAQ:ILMN) Issues FY25 Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its FY25 earnings guidance on Monday morning. The company provided earnings per share guidance of $4.50 for the period, compared to the consensus earnings per share estimate of $4.51.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Citigroup decreased their price target on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Piper Sandler upped their target price on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Guggenheim dropped their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Robert W. Baird decreased their price objective on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, March 5th. Finally, Canaccord Genuity Group lowered their price objective on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $149.25.

Illumina Price Performance

Shares of ILMN stock traded down $0.65 during trading hours on Monday, reaching $85.97. The company’s stock had a trading volume of 2,857,237 shares, compared to its average volume of 2,637,885. Illumina has a fifty-two week low of $80.18 and a fifty-two week high of $156.66. The firm’s 50 day simple moving average is $118.38 and its 200-day simple moving average is $131.48. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $13.62 billion, a price-to-earnings ratio of -11.19, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts forecast that Illumina will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.